Belatacept Pharmacokinetic Trial in Renal Transplantation

An Open-label Pharmacokinetic Study in De Novo Renal Transplant Subjects Receiving a Belatacept Based Immunosuppressant Regimen

The purpose of this study is to assess the pharmacokinetics and safety of belatacept in de novo renal transplant subjects treated with belatacept-based immunosuppressant medication

Inclusion Criteria:

• Recipient of a living or deceased donor kidney
• First or second transplant
• Men and women, including women of childbearing potential, 18 years and older

Exclusion Criteria:

• Panel reactive antibodies ≥ 30%
• Significant infection